


NOW
ARRIVED
10mg Tablet



- Effective control of symptoms.
- Resocialization and improved social performance.
- Low incidence of E.P.S.

once daily
Orap^{*}
pimozide

to help the schizophrenic patient
regain his place in society.

PRESCRIBING INFORMATION Presentation White, scored, uncoated tablets marked "Janssen" on one side and 0/2 on the other, each contains 2 mg pimozide. Pale green, scored, uncoated tablets marked "Janssen" on one side and 0/4 on the other, each contains 4 mg pimozide. White, scored, uncoated tablets marked "Janssen" on one side and 0/10 on the other, each contains 10 mg pimozide. Uses Orap* is an antipsychotic of the diphenyl butyl-piperidine series and is indicated for the treatment of acute or chronic schizophrenia. Hallucinations, delusions, thought disorders and emotional withdrawal respond well to lower doses of the drug. Higher doses may be needed for the control of acutely agitated, hyperactive or aggressive patients. **Dosage and Administration** Orap* is intended for oral administration to both adults and children. Patients may be maintained on a once daily dosage regime. As with all neuroleptics, it is important to determine the dose of Orap* according to the individual response of each patient. **In adults:** Dosage ranges between 2-20 mg daily. The usual initial dose is 4-10 mg, which may be varied according to response and tolerance to achieve an optimum maintenance dosage. In the acutely agitated patient the initial dose is 20 mg. Gradual reduction to the lowest effective maintenance dose may be attempted once control of symptoms is achieved. **In children:** In children over 12 years of age dosage should normally be 1-3 mg daily. Clinical experience in young children is limited and, therefore, Orap* should be used at the physician's discretion in children under 12 years of age. **Contra-Indications, warnings, etc.** **Contra-indications:** Although no teratological changes have been observed in experimental animals, the drug should not be administered to pregnant women. **Warnings:** Endogenous depression, pre-existing Parkinson's disease and epilepsy may be aggravated. **Overdosage:** There is no specific antidote to an overdose of pimozide. Cases should be treated symptomatically. A suicide attempt with 100 mg pimozide produced only slight tremor and another with 200 mg showed no specific side-effects and needed no treatment. **Side-effects:** Extra-pyramidal effects may occur at higher dosage levels. Occasional skin rashes have been reported. Glycosuria has been reported following Orap* administration, but it has not been established whether this effect was drug related. **Pharmaceutical precautions** Nil. **Legal category** POM. **Package quantities** Orap* tablets each containing 2 mg pimozide are supplied in packs of 100, 500 and 2,500. Orap* tablets each containing 4 mg pimozide are supplied in a pack of 250. Orap* tablets each containing 10 mg pimozide are supplied in a pack of 100. **Further information** Nil. **Product licence numbers** Orap* 2 mg 0242/5010, Orap* 4 mg 0242/0038, Orap* 10 mg 0242/0069. **Basic N.M.S. Cost** 10p-97p/day (4 mg x 250 pack) depending on dosage (2 mg-20 mg). (Correct at time of printing)



Further information is available and will gladly be supplied on request:

Psychiatric Information Service. Janssen Pharmaceutical Ltd, Janssen House, Chapel Street, Marlow, Bucks. SL7 1ET

Orap* is a trademark

NOTES FOR CONTRIBUTORS

PAPERS Papers for publication should be addressed to the Editor, Professor Michael Shepherd, Institute of Psychiatry, De Crespigny Park, Denmark Hill, London SE5 8AF. Contributors should send at least three copies of the text, tables, and figures. Copies other than the first may be xeroxed. The S.I. system should be adopted for text and figures. A short synopsis of about 50 words should be provided at the beginning of each article. Foreign quotations and phrases should be followed by a translation. Submission of a paper will be held to imply that it contains original work that has not been previously published and that it is not being submitted for publication elsewhere.

In addition to longer articles, the Editor is prepared to accept preliminary communications of between 1500 and 2000 words.

Manuscripts must be typewritten on one side of the paper in double-spacing with wide margins. The following information must be given on a single separate sheet: (1) title and short title for running head (not more than 100 characters); (2) authors' names, and (3) department in which work was done. Footnotes on the same sheet should list: (i) the authors' present addresses if different from departments in which work was done; (ii) name and address of the author to whom correspondence should be addressed; (iii) receipt of grants. Authors who would like a reprint address to be printed should include this on their manuscript.

REFERENCES (1) In the text these should follow the Harvard system – that is, name followed by date: Brown (1970). If there are more than two authors: the first author's name followed by *et al.* should be used, even the first time that the reference appears. (2) The list of references should be typed in alphabetical order on a separate sheet and should appear as follows: Brown, J., Williams, E. & Wright, H. (1970). Treatment of heroin addiction. *Psychological Medicine* 1, 134–136. Journal titles should be given in full.

Books should be cited as follows: Brown, J. (1970). *Psychiatric Research*. Smith: Glasgow.

ILLUSTRATIONS Only essential figures and tables should be included. *Photographs* Unmounted photographs on glossy paper should be provided. Magnification scales, if necessary, should be lettered on these. Where possible, prints should be trimmed to column width (i.e. 70 mm). *Diagrams* These will usually be reduced to 70 mm wide. Lettering should be in either Letraset or stencil, and care should be taken that lettering and symbols are of comparable size. Illustrations should not be inserted in the text, they should be marked on the back with figure numbers, title of paper, and name of author. All photographs, graphs, and diagrams should be referred to as figures and should be numbered consecutively in the text in Arabic numerals. The legends for illustrations should be typed on a separate sheet. *Tables* Tables should be numbered consecutively in the text in Arabic numerals and each typed on a separate sheet.

PROOFS AND OFFPRINTS Page proofs will be sent to the senior author. Corrections other than printer's errors may be charged to the author. Fifty offprints of each paper are supplied free; additional offprints are available according to a scale of charges if they are ordered when the proof is returned.

Psychological Medicine

Volume 11 Number 2 May 1981

CONTENTS

EDITORIALS

Cerebral laterality and psychopathology: fact and fiction	page 219
Epidemiology and depression	229
SEDGWICK, P.	
Michel Foucault: the anti-history of psychiatry	235
NAYLOR, G. J. AND SMITH, A. H. W.	
Vanadium: a possible aetiological factor in manic depressive illness	249
NAYLOR, G. J. AND SMITH, A. H. W.	
Defective genetic control of sodium-pump density in manic depressive psychosis	257
KRÄUPL TAYLOR, F.	
On pseudo-hallucinations	265
SCHARFETTER, C.	
Ego-psychopathology: the concept and its empirical evaluation	273
TSUANG, M. T., WOOLSON, R. F. AND SIMPSON, J. C.	
An evaluation of the Feighner criteria for schizophrenia and affective disorders using long-term outcome data	281
LITTLEWOOD, R. AND LIPSEGE, M.	
Some social and phenomenological characteristics of psychotic immigrants	289
LITTLEWOOD, R. AND LIPSEGE, M.	
Acute psychotic reactions in Caribbean-born patients	303
COCHRANE, R. AND STOPES-ROE, M.	
Psychological symptom levels in Indian immigrants to England – a comparison with native English	319
FALLOON, I. R. H. AND TALBOT, R. E.	
Persistent auditory hallucinations: coping mechanisms and implications for management	329
KENDELL, R. E., RENNIE, D., CLARKE, J. A. AND DEAN, C.	
The social and obstetric correlates of psychiatric admission in the puerperium	341
GIBBENS, T. C. N., SOOTHILL, K. L. AND WAY, C. K.	
Sex offences against young girls: a long-term record study	351
LOW, A. A., FARMER, R. D. T., JONES, D. R. AND ROHDE, J. R.	
Suicide in England and Wales: an analysis of 100 years, 1876–1975	359
BENJAMINSEN, S.	
Stressful life events preceding the onset of neurotic depression	369
TENNANT, C., BEBBINGTON, P. AND HURRY, J.	
The role of life events in depressive illness: is there a substantial causal relation?	379
CREED, F. AND MURRAY, R. M.	
The teaching of clinical skills at a postgraduate hospital	391
BRIEF COMMUNICATIONS	
(Des-Tyr ¹)- γ -endorphin in the treatment of schizophrenia R. MANCHANDA AND S. R. HIRSCH	401
Lack of effect of naloxone and schizophrenic auditory hallucinations C. P. L. FREEMAN AND C. G. FAIRBURN	405
PRELIMINARY COMMUNICATIONS	
Continuation therapy with lithium and amitriptyline in unipolar depressive illness: a controlled clinical trial A. I. M. GLEN, A. L. JOHNSON AND M. SHEPHERD	409
Social work effectiveness in the management of depressed women: a clinical trial R. H. CORNEY	417
Emotional disturbance in multiple sclerosis patients: validity of the General Health Questionnaire (GHQ) P. V. RABINS AND B. R. BROOKS	425
BOOK REVIEWS	429

© Cambridge University Press 1981

CAMBRIDGE UNIVERSITY PRESS

The Pitt Building, Trumpington Street, Cambridge CB2 1RP

32 East 57th Street, New York, N.Y. 10022

Printed in Great Britain at the University Press, Cambridge